Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers

NeuroImage

Volumn 64, Issue 1, 2013, Pages 75-90

  De Simoni, S ^a   Schwarz, A J ^b,c   O'Daly, O G ^a   Marquand, A F ^a   Brittain, C ^b   Gonzales, C ^b   Stephenson, S ^a   Williams, S C R ^a   Mehta, M A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Ketamine; NMDAR; PhMRI; Test retest reliability

Indexed keywords

KETAMINE;

ADULT; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; CINGULATE GYRUS; DRUG BLOOD LEVEL; DRUG RESPONSE; GLUTAMATERGIC DYSFUNCTION; HEAD MOVEMENT; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; NERVE CELL NETWORK; NEUROANATOMY; NEUROLOGIC DISEASE; NEUROMODULATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREFRONTAL CORTEX; PRIORITY JOURNAL; STATISTICAL MODEL; SUPRACINGULATE CORTEX; TEMPORAL LOBE; TEST RETEST RELIABILITY; THALAMUS; VALIDATION STUDY; VOLUNTEER;

ADOLESCENT; ADULT; ANESTHETICS, DISSOCIATIVE; BRAIN; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; OXYGEN CONSUMPTION; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84867471011     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.09.037     Document Type: Article

References (76)

1. Abel K.M., Allin M.P., Kucharska-Pietura K., Andrew C., Williams S., David A.S., Phillips M.L. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum. Brain Mapp. 2003, 18:135-145.
2. Absalom A.R., Lee M., Menon D.K., Sharar S.R., De Smet T., Halliday J., Ogden M., Corlett P., Honey G.D., Fletcher P.C. Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers. Br. J. Anaesth. 2007, 98:615-623.
3. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 1999, 156:1646-1649.
4. Akaike H. A new look at the statistical model identification. IEEE Trans. Automatic Control 1974, 19:716-723.
5. Bond A.J., James D.C., Lader M.H. Physiological and psychological measures in anxious patients. Psychol. Med. 1974, 4:364-373.
6. Bond A.J., James D.C., Lader M.H. Sedative effects on physiological and psychological measures in anxious patients. Psychol. Med. 1974, 4:374-380.
7. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry 1997, 154:805-811.
8. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron 1997, 19:591-611.
9. Bremner J.D., Krystal J.H., Putnam F.W., Southwick S.M., Marmar C., Charney D.S., Mazure C.M. Measurement of dissociative states with the Clinician Administered Dissociative States Scale (CADSS). J. Trauma. Stress 1998, 11.
10. Burnham K.P., Anderson D.R. Model Selection and Multimodel Inference: a Practical Information-Theoretic Approach 2002, Springer-Verlag New York, Inc. 2nd ed.
11. Caceres A., Hall D.L., Zelaya F.O., Williams S.C., Mehta M.A. Measuring fMRI reliability with the intra-class correlation coefficient. Neuroimage 2009, 45:758-768.
12. Chin C.L., Upadhyay J., Marek G.J., Baker S.J., Zhang M., Mezler M., Fox G.B., Day M. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J. Pharmacol. Exp. Ther. 2011, 336:709-715.
13. Cilia J., Hatcher P., Reavill C., Jones D.N. (+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J. Psychopharmacol. 2007, 21:302-311.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, New Jersey. 2nd ed.
15. Corlett P.R., Honey G.D., Aitken M.R., Dickinson A., Shanks D.R., Absalom A.R., Lee M., Pomarol-Clotet E., Murray G.K., McKenna P.J., Robbins T.W., Bullmore E.T., Fletcher P.C. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch. Gen. Psychiatry 2006, 63:611-621.
16. Cotman C.W., Monaghan D.T., Ottersen O.P., Storm-Mathisen H. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci. 1987, 10(7):273-280.
17. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65:154-164.
18. Dedeurwaerdere S., Wintmolders C., Straetemans R., Pemberton D., Langlois X. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl) 2011, 214:505-514.
19. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 1998, 812:65-75.
20. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 1998, 787:181-190.
21. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 1999, 843:171-183.
22. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Ther. 2000, 293:8-14.
23. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition. Biometrics Research 2002, New York State Psychiatric Institute, New York.
24. Fleis J.L., Levin B., Paik M.C. Statistical Methods for Rates and Proportions 2003, John Wiley & Sons, Hoboken, NJ.
25. Freire L., Mangin J.F. Motion correction algorithms may create spurious brain activations in the absence of subject motion. Neuroimage 2001, 14:709-722.
26. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., Frackowiak R.S. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 1994, 2:189-210.
27. Friston K.J., Williams S., Howard R., Frackowiak R.S., Turner R. Movement-related effects in fMRI time-series. Magn. Reson. Med. 1996, 35:346-355.
28. Gilmour G., Dix S., Fellini L., Gastambide F., Plath N., Steckler T., Talpos J., Tricklebank M. NMDA receptors, cognition and schizophrenia - testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2011, 62(3):1401-1412.
29. Golanov E.V., Reis D.J. Cerebral cortical neurons with activity linked to central neurogenic spontaneous and evoked elevations in cerebral blood flow. Neurosci. Lett. 1996, 209:101-104.
30. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., Bifone A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008, 201:273-284.
31. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008, 33:1690-1703.
32. Gozzi A., Schwarz A., Crestan V., Bifone A. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine. Magn. Reson. Imaging 2008, 26:999-1006.
33. Hackler E.A., Byun N.E., Jones C.K., Williams J.M., Baheza R., Sengupta S., Grier M.D., Avison M., Conn P.J., Gore J.C. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience 2010, 168:209-218.
34. Herbert M., Johns M.W., Dore C. Factor analysis of analogue scales measuring subjective feelings before and after sleep. Br. J. Med. Psychol. 1976, 49:373-379.
35. 2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001, 25:165-172.
36. Honey R.A., Turner D.C., Honey G.D., Sharar S.R., Kumaran D., Pomarol-Clotet E., McKenna P., Sahakian B.J., Robbins T.W., Fletcher P.C. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003, 28:2037-2044.
37. Honey R.A., Honey G.D., O'Loughlin C., Sharar S.R., Kumaran D., Bullmore E.T., Menon D.K., Donovan T., Lupson V.C., Bisbrown-Chippendale R., Fletcher P.C. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology 2004, 29:1203-1214.
38. Iannetti G.D., Wise R.G. BOLD functional MRI in disease and pharmacological studies: room for improvement?. Magn. Reson. Imaging 2007, 25:978-988.
39. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 2004, 9(984-997):979.
40. Johnstone T., Ores Walsh K.S., Greischar L.L., Alexander A.L., Fox A.S., Davidson R.J., Oakes T.R. Motion correction and the use of motion covariates in multiple-subject fMRI analysis. Hum. Brain Mapp. 2006, 27:779-788.
41. Kiebel S.J., Poline J.B., Friston K.J., Holmes A.P., Worsley K.J. Robust smoothness estimation in statistical parametric maps using standardized residuals from the general linear model. Neuroimage 1999, 10:756-766.
42. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
43. Langsjo J.W., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., Sipila H., Kurki T., Silvanto M., Scheinin H. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003, 99:614-623.
44. Langsjo J.W., Salmi E., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., Viljanen T., Kurki T., Silvanto M., Scheinin H. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 2004, 100:1065-1071.
45. Langsjo J.W., Maksimow A., Salmi E., Kaisti K., Aalto S., Oikonen V., Hinkka S., Aantaa R., Sipila H., Viljanen T., Parkkola R., Scheinin H. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 2005, 103:258-268.
46. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol. Sci. 2000, 21:314-318.
47. Liao R., McKeown M.J., Krolik J.L. Isolation and minimization of head motion-induced signal variations in fMRI data using independent component analysis. Magn. Reson. Med. 2006, 55:1396-1413.
48. Lindquist M.A. The statistical analysis of fMRI data. Stat. Sci. 2008, 23:439-464.
49. Littlewood C.L., Jones N., O'Neill M.J., Mitchell S.N., Tricklebank M., Williams S.C. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006, 186:64-81.
50. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
51. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 1959, 81:363-369.
52. Mason O.J., Morgan C.J., Stefanovic A., Curran H.V. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr. Res. 2008, 103:138-142.
53. Mason O., Morgan C.J., Dhiman S.K., Patel A., Parti N., Curran H.V. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol. Med. 2009, 39:951-956.
54. McGraw K., Wong S. Forming inferences about some intraclass correlation coefficients. Psychol. Methods 1996, 1:30-46.
55. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
56. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17:2921-2927.
57. Morgan C.J., Perry E.B., Cho H.S., Krystal J.H., D'Souza D.C. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187(4):405-414.
58. Morgan H.L., Turner D.C., Corlett P.R., Absalom A.R., Adapa R., Arana F.S., Pigott J., Gardner J., Everitt J., Haggard P., Fletcher P.C. Exploring the impact of ketamine on the experience of illusory body ownership. Biol. Psychiatry 2011, 69:35-41.
59. Nehls D.G., Park C.K., MacCormack A.G., McCulloch J. The effects of N-methyl-d-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilisation. Brain Res. 1990, 511:271-279.
60. Nelson H.E., Willison J.R. The Revised National Adult Reading Test (Part II): Test Manual 1991, NFER-NELSON, Windsor.
61. Oakes T.R., Johnstone T., Ores Walsh K.S., Greischar L.L., Alexander A.L., Fox A.S., Davidson R.J. Comparison of fMRI motion correction software tools. Neuroimage 2005, 28:529-543.
62. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
63. Pendse G.V., Schwarz A.J., Baumgartner R., Coimbra A., Upadhyay J., Borsook D., Becerra L. Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile. J. Magn. Reson. Imaging 2010, 31:1445-1457.
64. Poldrack R.A., Mumford J.A., Nichols T.E. Handbook of Functional MRI Data Analysis 2011, Cambridge University Press.
65. Pouget P., Wattiez N., Rivaud-Pechoux S., Gaymard B. Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. Psychopharmacology 2010, 209(4):313-318.
66. Imaging Biomarkers in Drug Development: Case Studies 2011, Cambridge University Press. A. Schwarz, A. Tauscher (Eds.).
67. Schwarz A.J., Whitcher B., Gozzi A., Reese T., Bifone A. Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. J. Neurosci. Methods 2007, 159:346-360.
68. Schwedler M., Miletich D.J., Albrecht R.F. Cerebral blood flow and metabolism following ketamine administration. Can. Anaesth. Soc. J. 1982, 29:222-226.
69. Shah Y.B., Marsden C.A. The application of functional magnetic resonance imaging to neuropharmacology. Curr. Opin. Pharmacol. 2004, 4:517-521.
70. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 86:420-428.
71. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry 1998, 155:1009-1015.
72. Steward C.A., Marsden C.A., Prior M.J., Morris P.G., Shah Y.B. Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berl) 2005, 180:687-704.
73. Storm-Mathisen J., Leknes A.K., Bore A.T., Vaaland J.L., Edminson P., Haug F.M., Ottersen O.P. First visualization of glutamate and GABA in neurones by immunocytochemistry. Nature 1983, 301:517-520.
74. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur. Neuropsychopharmacol. 1997, 7:25-38.
75. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J., Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 1997, 7:9-24.
76. Whitcher B., Schwarz A.J., Barjat H., Smart S.C., Grundy R.I., James M.F. Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. Neuroimage 2005, 24:281-295.